On April 3, 2017 ONCODESIGN (FR0011766229 – ALONC), a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, reported that it will present its latest scientific developments at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017 held on April 1-5, in Washington DC, USA (Press release, Oncodesign, APR 3, 2017, View Source [SID1234518433]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) is the largest global organisation that brings together public and private actors involved in cancer research. Its annual meetings attract every year over 18,000 researchers from the industry and academia.

On this occasion, Oncodesign will present several of its recent scientific developments:

As part of the IMODI project, Oncodesign will present a poster on one of the more important collections of extensively characterised predictive models for pancreatic cancer in the world. The collection of breast cancer models, particularly documented and representative of the human disease, caught the attention of the organisers of the AACR (Free AACR Whitepaper) meeting and will be presented during a dedicated conference on April 4, 2017. According to the INCA study, breast cancer is the cancer with highest incidence in women, with over 54,000 new cases each year in France.
As part of the IMAkinib project, Oncodesign will present the preclinical, cellular and in vivo imaging results obtained with its first PET-tracer generated by the Nanocyclix technology, currently in phase 1 of its development in patients with non-small cell lung cancer.
Oncodesign will also present the results of its Experimentation’s research activities on a new immunotherapy formulation conducted for the US company Checkmate Pharmaceuticals (Cambridge, MA). Remarkable efficacy results have been obtained, in combination with immune checkpoint modulators, in several cancer indications.
Finally, Oncodesign will describe in a fourth poster Experimentation’s internal research conducted on the resistance to PD-11 blockade. Antibodies targeting PD-1 have been recently approved as second line treatments for several types of cancer (urethra, kidney, head and neck, Hodgkin’s lymphoma), or as first line treatment for metastatic melanoma and metastatic non-small cell lung cancer. In spite of the positive response rates and increased survival in the majority of treated patients, a resistance phenomenon develops in certain patients. The Oncodesign research presented at the AACR (Free AACR Whitepaper) meeting aims to develop combination strategies to overcome such resistance and to identify biomarkers. This research showcases complex data analyses, such as cytokine profiles studied in syngeneic models.
Jan Hoflack, Ph.D., Chief Scientific Officer of Oncodesign, said: "Being represented in this way in one of the largest global medical meetings on oncology is a privilege, which provides unparalleled visibility to Oncodesign. This reinforces further the reputation of Oncodesign in terms of its research quality, upheld by the commitment of all our teams to promote the discovery of more effective new drugs."

Full details on Oncodesign presentations during the AACR (Free AACR Whitepaper) meeting:

Abstract n°5169: "Overcoming pd1 targeting antibody resistance using combination strategies"
Presentation: Dr. Jean-François Mirjolet (Oncodesign, Dijon, France)
Poster session/Section: Poster Section 28
Date: April 3, 2017
Time: 8:00am – 12:00pm EDT
Venue: Convention Center, Halls A-C

Abstract n°52217: "Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors"
Presentation: Dr. Francis Bichat (Oncodesign, Dijon, France)
Poster session/Section: Poster Section 39
Date: April 3, 2017
Time: 8:00am – 12:00pm EDT
Venue: Convention Center, Halls A-C

Abstract n°28: "Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models"
Presentation: Dr. Aaron Morris (Checkmate Pharmaceuticals, Boston, US) and
Dr Sylvie Maubant (Oncodesign, Dijon, France)
Poster session/Section: Poster Section 26
Date: April 3, 2017
Time:
1:00pm – 5:00pm EDT
Venue: Convention Center, Halls A-C

Abstract n°3846: "Imodi initiative: A novel holistic and integrative approach with patient-derived tumor models against pancreatic cancer"
Presentation: Dr. Juan Iovanna (Inserm U1068, Marseille, France)
Poster session/Section: Poster Section 37
Date: April 4, 2017
Time: 8:00am – 12:00pm EDT
Venue: Convention Center, Halls A-C

Abstract n°5015: "Innovative and predictive models against breast cancer"
Presentation: Dr. S. Tabonne (Leon Berard clinical center, Lyon, France)
Section: Tumor biology Minisymposium session
Date: April 4, 2017
Time:
3:00pm – 5:00pm EDT